# Arcutis Biotherapeutics, Inc. clinical trials: 26 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials with Arcutis Biotherapeutics, Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Arcutis Biotherapeutics, Inc.: 26 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/arcutis-biotherapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 4, 2026 | NCT07916480 | Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | Phase 3 | Recruiting | Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema) | 415 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916480) |
| March 6, 2026 | NCT07453602 | Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 | Arcutis Biotherapeutics, Inc. | Phase 1 | Recruiting | Atopic Dermatitis (AD), Eczema | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453602) |
| January 14, 2026 | NCT07340216 | Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis | Arcutis Biotherapeutics, Inc. | Phase 1 | Completed | Psoriasis | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07340216) |
| May 31, 2025 | NCT06998056 | Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | Atopic Dermatitis (Eczema) | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06998056) |
| August 31, 2021 | NCT05028582 | Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) | Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | Scalp Psoriasis | 432 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05028582) |
| July 22, 2021 | NCT04973228 | Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) | Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | Seborrheic Dermatitis | 457 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04973228) |
| April 15, 2021 | NCT04845620 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) | Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | Atopic Dermatitis Eczema | 652 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04845620) |
| March 23, 2021 | NCT04811131 | Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo | Arcutis Biotherapeutics, Inc. | Phase 2 | Terminated | Vitiligo | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04811131) |
| March 18, 2021 | NCT04804605 | Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | Atopic Dermatitis Eczema | 1,220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04804605) |
| February 26, 2021 | NCT04773600 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) | Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | Atopic Dermatitis Eczema | 683 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04773600) |
| February 26, 2021 | NCT04773587 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | Atopic Dermatitis Eczema | 654 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04773587) |
| February 10, 2021 | NCT04746911 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) | Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | Psoriasis, Plaque Psoriasis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04746911) |
| December 7, 2020 | NCT04655313 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) | Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | Psoriasis, Plaque Psoriasis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04655313) |
| June 24, 2020 | NCT04445987 | Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | Seborrheic Dermatitis | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04445987) |
| May 7, 2020 | NCT04378569 | Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema | Arcutis Biotherapeutics, Inc. | Phase 1/2 | Completed | Chronic Hand Eczema | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04378569) |
| February 27, 2020 | NCT04286607 | Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | Chronic Plaque Psoriasis | 337 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04286607) |
| February 20, 2020 | NCT04279119 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis | Arcutis Biotherapeutics, Inc. | Phase 1 | Completed | Plaque Psoriasis | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04279119) |
| December 26, 2019 | NCT04211389 | Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | Chronic Plaque Psoriasis | 442 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04211389) |
| December 26, 2019 | NCT04211363 | Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | Arcutis Biotherapeutics, Inc. | Phase 3 | Completed | Chronic Plaque Psoriasis | 439 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04211363) |
| November 7, 2019 | NCT04156191 | Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema | Arcutis Biotherapeutics, Inc. | Phase 1 | Completed | Atopic Dermatitis (Eczema) | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04156191) |
| October 16, 2019 | NCT04128007 | Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis | Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | Plaque Psoriasis | 304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04128007) |
| September 17, 2019 | NCT04091646 | Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | Seborrheic Dermatitis | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04091646) |
| April 16, 2019 | NCT03916081 | Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | Atopic Dermatitis | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03916081) |
| December 5, 2018 | NCT03764475 | Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis | Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | Plaque Psoriasis | 332 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03764475) |
| August 20, 2018 | NCT03638258 | The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis | Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | Plaque Psoriasis | 331 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03638258) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 2 |
| Phase 2 | 10 |
| Phase 3 | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Recruiting | 2 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dermatitis, Atopic | 5 |
| Eczema | 4 |
| Psoriasis | 4 |
| Dermatitis, Seborrheic | 3 |
| Vitiligo | 1 |
| Pruritus | 1 |
| Dermatitis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Private equity firms in the United States](https://specstream.ai/data/businesses/private-equity-firms/united-states)
- [Produce wholesalers in the United States](https://specstream.ai/data/businesses/produce-wholesalers/united-states)
- [Prosthetics providers in the United States](https://specstream.ai/data/businesses/prosthetics-providers/united-states)
- [Public adjusters in the United States](https://specstream.ai/data/businesses/public-adjusters/united-states)
- [Publishers in the United States](https://specstream.ai/data/businesses/publishers/united-states)
- [Rail freight companies in the United States](https://specstream.ai/data/businesses/rail-freight-companies/united-states)
